Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142426

Published: 2020

Journal Articles

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

James B Rottman, DVM, PhD DACVP, Kenneth Ganley, BS, Brenna Daly, BS, Holly M. Horton, PhD, Kevin M. Friedman, Molly Perkins, PhD, Shannon Grande, PhD, Claire J Rhodes, BS, Richard A. Morgan, PhD, Christopher J. Horvath, DVM, MS, DACVP

Blood (2017) 130 (Supplement 1): 4450.

https://doi.org/10.1182/blood.V130.Suppl_1.4450.4450

Published: 2017

Journal Articles

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

Michael S Magee, PhD, Iulia Diaconu, PhD, Mark Pogson, PhD, Ankit Gupta, PhD, Amy Jensen-Smith, PhD, Brian Collette, BS, Andrew Chavkin, MS, Eli Pasackow, BS, Aaron Edwards, MS, Kevin M. Friedman, Alexander Astrakhan, PhD, Michael T Certo, PhD, Jordan Jarjour, PhD, Richard A. Morgan, PhD

Blood (2017) 130 (Supplement 1): 1906.

https://doi.org/10.1182/blood.V130.Suppl_1.1906.1906

Published: 2017

Journal Articles

A Novel TGF-β 2 /Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β 2 -Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks

Benjamin Boyerinas, Sara M. Miller, Ryan C. Murray, John W. Evans, Geoffrey B. Parsons, Katherine J. Seidl, Kevin M. Friedman, Richard A. Morgan, PhD

Blood (2017) 130 (Supplement 1): 1911.

https://doi.org/10.1182/blood.V130.Suppl_1.1911.1911

Published: 2017

Journal Articles

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Graham Lilley, M.S., Alden Ladd, Daniel Cossette, Laura Viggiano, Gregory Hopkins, John W. Evans, PhD, Mingli Li, M.S., Howard J. Latimer, IV, BS, Sara M. Miller, Michael Kuczewski, MS, Wendy Bakeman, Kayla MacLeod, Kevin M. Friedman, PhD, Dawn A Maier, M.S., Michael Paglia, M.S., Richard A. Morgan, PhD, Mark D Angelino, PhD

Blood (2015) 126 (23): 3243.

https://doi.org/10.1182/blood.V126.23.3243.3243

Published: 2015

Journal Articles

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

Molly R. Perkins, D.Phil., Shannon Grande, PhD, Amanda Hamel, BS, Holly M. Horton, PhD, Tracy E. Garrett, BA, Sara M. Miller, Howard J. Latimer, IV, BS, Christopher J. Horvath, DVM, MS, DACVP, Michael Kuczewski, MS, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 1893.

https://doi.org/10.1182/blood.V126.23.1893.1893

Published: 2015

Journal Articles

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Alena A. Chekmasova, PhD, Holly M. Horton, PhD, Tracy E. Garrett, BA, John W. Evans, PhD, Johanna Griecci, BS, Amanda Hamel, BS, Howard J. Latimer, IV, BS, Stacie L. Seidel, MA, Byoung Y. Ryu, PhD, Michael Kuczewski, MS, Christopher J. Horvath, DVM, MS, DACVP, Kevin M. Friedman, PhD, Richard A. Morgan, PhD

Blood (2015) 126 (23): 3094.

https://doi.org/10.1182/blood.V126.23.3094.3094

Published: 2015

NARROW

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

A Novel TGF-β 2 /Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β 2 -Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Email alerts

ASH Publications

American Society of Hematology

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

ROR1-Directed Chimeric Antigen Receptor T Cell Recognition of Self-Antigen Is Associated with Acute Toxicity, T Cell Dysfunction, and Poor Tumor Control.

Gene Editing of TRAC Locus Utilizing Megatal Nucleases Increases Expression of Transgenic TCRs Delivered Via Lentiviral Vector-Mediated Gene Transfer

A Novel TGF-β 2 /Interleukin Receptor Signal Conversion Platform That Protects CAR/TCR T Cells from TGF-β 2 -Mediated Immune Suppression and Induces T Cell Supportive Signaling Networks

Characterization of Lentiviral Vector Derived Anti-Bcma CAR T Cells Reveals Key Parameters for Robust Manufacturing of Cell-Based Gene Therapies for Multiple Myeloma

Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells

A Novel and Highly Potent CAR T Cell Drug Product for Treatment of BCMA-Expressing Hematological Malignances

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only